Roche Holding AG (RO)

342.20
-0.80(-0.23%)
  • Volume:
    17,105
  • Bid/Ask:
    342.00/342.40
  • Day's Range:
    341.00 - 343.60
Trading near 52-week Low

Roche Holding has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

RO Historical Data

Time Frame:
Daily
12/28/2022 - 01/28/2023
342.20342.80343.60341.0017.11K-0.23%
343.00342.00346.00342.0036.59K+0.06%
342.80348.80348.80341.0032.47K-1.61%
348.40350.00350.80347.8014.65K-0.34%
349.60348.60350.20346.0028.17K+0.46%
348.00350.00352.40348.0023.61K-0.74%
350.60351.40355.80350.6029.04K-1.30%
355.20352.00356.60350.8035.87K+0.68%
352.80350.60353.80350.6031.40K+0.40%
351.40350.00351.60349.0014.02K+0.98%
348.00346.80349.20346.2023.85K+0.52%
346.20348.00350.00343.0038.35K-0.23%
347.00353.00353.20347.0061.36K-1.76%
353.20350.00354.40349.0025.32K-0.11%
353.60354.20355.40352.2029.87K-0.95%
357.00355.00357.00353.8023.25K+0.73%
354.40360.00361.60354.4031.97K-2.10%
362.00363.80366.40361.2038.78K-0.06%
362.20358.80364.80358.6025.40K+1.06%
358.40365.80365.80358.4015.07K-1.38%
363.40361.40363.40359.0019.73K+0.28%
362.40363.00363.40359.6014.68K-0.22%
Highest: 366.40Lowest: 341.00Difference: 25.40Average: 352.35Change %: -5.78
  • A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
    1
    • 13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
      0
      • Just like Biolidics. they get approval for Covid19 tests kits in USA
        0
        • i dont know
          0
          • is the historical price adjusted for stock splits?
            0
            • i dont know
              0